Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000484303 | SCV000565746 | uncertain significance | not provided | 2015-09-15 | criteria provided, single submitter | clinical testing | This variant is denoted CDKN2A c.274T>C at the cDNA level, p.Ser92Pro (S92P) at the protein level, and results in the change of a Serine to a Proline (TCT>CCT) of the p14-ARF protein. The CDKN2A gene encodes the p16 protein and, using an alternate reading frame, the p14-ARF protein as well. Of note, this variant also results in a change to the p16 protein; however, that amino acid substitution is silent (p.Thr77Thr). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. CDKN2A Ser92Pro was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Serine and Proline differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. CDKN2A Ser92Pro occurs at a position that is not conserved and is not located in a known functional domain (UniProt). In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available information, it is unclear whether CDKN2A Ser92Pro is pathogenic or benign. We consider it to be a variant of uncertain significance. |
Ambry Genetics | RCV004023110 | SCV005032105 | likely benign | Hereditary cancer-predisposing syndrome | 2023-11-25 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |